Гиппократ не рад. Путеводитель в мире медицинских исследований

44. Российское общество урологов, Ассоциация онкологов России & Российское общество онкоурологов. Клинические рекомендации: рак предстательной железы. (2016).

45. Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004720.pub3

46. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).

47. Chen, J. et al. Identification of a novel TIF-IA – NF-κB nucleolar stress response pathway. Nucleic Acids Res. 46, 6188–6205 (2018).

48. Hudson, A. L. & Colvin, E. K. Transgenic Mouse Models of SV40-Induced Cancer. ILAR J. 57, 44–54 (2016).

49. Council, I. of M. and N. R. Use of Laboratory Animals in Biomedical and Behavioral Research. (National Academies Press, 1988). doi:10.17226/1098

50. Malhi, G. S., Tanious, M., Das, P., Coulston, C. M. & Berk, M. Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs 27, 135–153 (2013).

51. Lithium’s Mechanism of Action – A Focus on Neuroprotection. 23, (2017).

52. Lithium’s Hypothetical Mechanism of Action. Available at: https://www.youtube.com/watch?v=iNH0GdldxYs. (Accessed: 5th January 2019)

53. Shorter, E. The history of lithium therapy. Bipolar Disord. 11 Suppl 2, 4–9 (2009).

54. Nikiphorou, E., Uksila, J. & Sokka, T. A cross-sectional study of vitamin D levels in a large cohort of patients with rheumatic diseases. Clin. Rheumatol. 37, 803–810 (2018).

55. Ilic, M. & Ilic, I. Epidemiology of pancreatic cancer. World J. Gastroenterol. 22, 9694–9705 (2016).

56. Streicher, S. A., Yu, H., Lu, L., Kidd, M. S. & Risch, H. A. Case-Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiol. Biomarkers Prev. 23, 1254–1263 (2014).

57. Framingham Heart Study. Available at: https://www.framinghamheartstudy.org/. (Accessed: 10th January 2019)

58. Framingham Risk Score for Hard Coronary Heart Disease. doi:10.1056/NEJM199006073222304

59. SCORE Risk Charts. Available at: https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts. (Accessed: 18th December 2017)

60. NHS3 – Looking forward, connecting to the past. Available at: http://nhs2survey.org/wordpress/. (Accessed: 10th January 2019)

61. Lynch, J. J., Frederick Fregin, G., Mackie, J. B. & Monroe, R. R. Heart Rate Changes in the Horse to Human Contact. Psychophysiology 11, 472–478 (1974).

62. Keller, A., Akintola, T. & Colloca, L. Placebo Analgesia in Rodents: Current and Future Research. Int. Rev. Neurobiol. 138, 1–15 (2018).

63. Grevert, P., Albert, L. H. & Goldstein, A. Partial antagonism of placebo analgesia by naloxone. Pain 16, 129–43 (1983).

64. Benedetti, F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64, 535–43 (1996).

65. Levine, J. D., Gordon, N. C. & Fields, H. L. The mechanism of placebo analgesia. Lancet (London, England) 2, 654–7 (1978).

66. Price, D. D., Craggs, J., Nicholas Verne, G., Perlstein, W. M. & Robinson, M. E. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 127, 63–72 (2007).

67. Wager, T. D. et al. Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain. Science (80-.). 303, 1162–1167 (2004).

68. Wager, T. D., Scott, D. J. & Zubieta, J.-K. Placebo effects on human mu-opioid activity during pain. Proc. Natl. Acad. Sci. U. S. A. 104, 11056–61 (2007).

69. de la Fuente-Fernández, R., Lidstone, S. & Stoessl, A. J. Placebo effect and dopamine release. J. Neural Transm. Suppl. 415–8 (2006).

70. Wager, T. D. & Atlas, L. Y. The neuroscience of placebo effects: connecting context, learning and health. Nat. Rev. Neurosci. 16, 403–18 (2015).

71. Häuser, W., Hansen, E. & Enck, P. Nocebo Phenomena in Medicine. Dtsch. Ärzteblatt Int. 109, 459–65 (2012).

72. Petrie, K. J. & Rief, W. Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. Annu. Rev. Psychol. 70, 599–625 (2019).

73. Crichton, F., Dodd, G. expectations produce symptoms from infrasound associated with wind turbines?orge, Schmid, G., Gamble, G. & Petrie, K. J. Can expectations produce symptoms from infrasound associated with wind turbines? Heal. Psychol. 33, 360–364 (2014).

74. Cannon, C. P. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).